[Clinical studies on gentamicin for infectious diseases following intravenous drip infusion]. 1983

T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi

An antibiotic drug of aminoglycoside group, gentamicin (GM) for parenteral use was used to 14 hospitalized patients; 5 with acute or subacute cholecystitis, 6 with acute peritonitis (4 cases were due to acute appendicitis, a case was torsion of right ovarian cyst and a case was cecal CROHN's disease), 1 with fistula ani and abscess, and 2 with localized peritonitis after gastrectomy due to gastric ulcer. GM in a dose of 60 mg were administered by intravenous drip infusion for 1 to 2 hours, twice a day for 4 to 12 days. To the cases of biliary tract infection, GM was treated for preoperative chemotherapy and to the other cases GM was treated for postoperative chemotherapy. Clinical response was excellent in 7 cases, good in 6 cases, fair in 1 case and poor in none. No adverse effect was observed. The organisms were isolated in 7 cases, 7 were Escherichia coli, 2 were Klebsiella pneumoniae and 3 were Bacteroides fragilis. The MICs for GM were 0.78--1.56 micrograms/ml in 10(8) and 10(6) cells/ml, except B. fragilis. Before the operation of above cases, GM in a dose of 60 mg (a case was 40 mg) were administered by intravenous drip infusion for 1 to 2 hours in 7 cases (3 biliary tract infection, 2 acute peritonitis and 2 gastric ulcer) and 7 cases by intramuscularly. The materials of common duct bile, gall bladder bile, gall bladder wall, the appendix and other tissues, ascites and serum samples were taken during the operation. GM concentration was measured by bioassay method with Bacillus subtilis ATCC 6633 as test organism. GM concentrations in bile and gall bladder wall after intravenous drip infusion were higher than those after intramuscular administration. In the appendicitis with localized peritonitis, GM concentration in the appendix wall with catarrhal appendicitis was 0.90 microgram/g after intramuscular administration. In the cases with diffuse peritonitis and catarrhal appendicitis, GM concentrations in appendixes were 1.18 micrograms/g and 1.37 micrograms/g after intravenous drip infusion. Therefore, it was supposed that GM could be used safety and usefully by intravenous drip infusion than that by intramuscular administration.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011292 Premedication Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION. Premedications
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002764 Cholecystitis Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases. Empyema, Gallbladder,Gallbladder Inflammation,Empyema, Gall Bladder,Gall Bladder Empyema,Gallbladder Empyema,Inflammation, Gallbladder

Related Publications

T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi
May 1988, The Japanese journal of antibiotics,
T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi
January 1983, The Japanese journal of antibiotics,
T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi
May 1988, The Japanese journal of antibiotics,
T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi
November 1986, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi
September 1981, The Japanese journal of antibiotics,
T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi
February 1983, The Japanese journal of antibiotics,
T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi
April 1981, The Japanese journal of antibiotics,
T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi
August 1984, The Japanese journal of antibiotics,
T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi
September 1981, The Japanese journal of antibiotics,
T Nakamura, and I Hashimoto, and Y Sawada, and J Mikami, and M Saitoh, and K Hattanda, and E Bekki, and H Nishindai, and M Nakanishi, and Y Kasai, and K Deguchi
November 1981, The Japanese journal of antibiotics,
Copied contents to your clipboard!